Monosol Rx, LLC
MonoSol Rx is a specialty pharmaceutical company leveraging its proprietary PharmFilm® technology to deliver unique proprietary pharmaceutical drug films. PharmFilm® is designed to benefit patients by improving the convenience, efficacy, and compliance of new and currently marketed drugs. The Company's leadership in film drug delivery is supported by strong intellectual property, a portfolio of commercialized over-the-counter (OTC) drug products, and a development pipeline of prescription formulations based on PharmFilm® technology.
On May 22nd 2008, APR entered into a Collaboration and Partnership Agreement with the US corporation Monosol Rx, Inc. located in Warren, New Jersey, US ("Monosol") for the joint development, manufacturing and out licensing of 2 specific RapidFilm drug candidates namely Ondansetron and Donepezil. On December 24th, 2009, APR entered into a Marketing Agreement for the registration and licensing in the countries of Europe of up to 3 new Oral Film Strips drug candidates.
Founded in 1990, Labtec GmbH is one of the leading drug delivery development companies focusing on transdermal and topical patches, as well as fast dissolving oral films based on its proprietary Rapidfilm® technology. Labtec is a subsidiary of tesa SE - a member of the Beiersdorf group of companies - and represents tesa's pharmaceutical business. The company offers contract development and contract manufacturing of patches and oral film strips to the pharmaceutical industry.
On November 2005, APR entered into a strategic Partnership Agreement with Labtec for the identification, development and licensinf of Oral Dispersible Film strip candidates; in addition on January 2001, APR entered into a Partnership Agreement for the development and licensing of a consumer OTC product in patch form containing and releasing volatile essential oils to be used as nasal decongestant (the "Decongestant Patch").
Fidia Farmaceutici SpA
Fidia Group is Italian and has firm foundations in that country. It has a long tradition of top-quality products, fruit of years of careful scientific research. Fidia and partners sell their products worldwide, through commercial agreements with multinationals in the pharmaceutical and medical sectors. On December 21st 2001, APR entered into a Partnership Agreement (the "Partnership Agreement") with the Italian Company Fidia Farmaceutici S.p.A. located in Abano Terme, Italy ("Fidia") for the development and licensing of a Diclofenac Matrix Patch (the "Diclo Patch" or the "Product").
Bioselenia is a European service and consulting company in the life science area founded by Mr. Pierfrancesco Maschio and focused on transaction services
(in & out licensing, asset acquisition and divestments, company merger and acquisitions) as well as on business development operations; Bioselenia is
headquartered in Milan with subsidiaries in selected EU countries enables Bioselenia to provide global services with deep local knowledge of specific market
On 2008, APR acquired a minortiiy equity position into Bioselenia..
Nautilus Neurosciences, Inc.
Nautilus Neurosciences is a neurology-focused specialty pharmaceutical company committed to providing the health care community with medically relevant products and services that directly benefit those affected by neurologic disorders. Nautilus is backed by Tailwind Capital and Galen Partners. For more information, visit www.nautilusneurosciences.com